UPCC 57418: A Phase III Multicenter Randomized Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
Enrolling By Invitation
99 years or below
All
Phase
3
1 Location
Brief description of study
This is a study of the effectiveness and safety of giving the experimental drug, APR-246, together with the drug azacitidine to patients with MDS that has not yet been treated with chemotherapy or hypomethylating agents like azacitidine, compared with just giving azacitidine alone.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Myelodysplastic Syndromes
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 832565
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
